Welcome to our dedicated page for Amylyx Pharmaceuticals SEC filings (Ticker: AMLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Amylyx Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Amylyx Pharmaceuticals's regulatory disclosures and financial reporting.
AMLX Form 144 notice reports proposed transfer related to the vesting of restricted stock units into Common stock. The filing lists 17,105 shares associated with 03/02/2026 and records a sale of 6,580 Common shares by Camille L Bedrosian on 12/01/2025.
Issuer files a Form 144 reporting the sale of common stock tied to vested restricted stock units and recent brokered transactions. The filing lists 22,522 shares associated with a 03/02/2026 vesting event and shows prior sales of 3,326 (01/06/2026) and 3,557 (02/02/2026) by James M. Frates.
The report names Morgan Stanley Smith Barney LLC as the broker and references NASDAQ as the market; timing and cash‑flow details are those shown on the reported trade dates.
AMLX lists insider resale activity by Joshua B. Cohen: a planned disposition of 57,529 common shares tied to vesting restricted stock units on 03/02/2026 and multiple sales in the prior three months. The excerpt shows sales of 7,715 (01/06/2026), 136,193 (01/15/2026), 1,974 (01/16/2026), and 15,500 (02/02/2026).
AMLX reports a Form 144 disclosure covering recent transactions in its common stock. The issuer recorded the vesting of 20,545 restricted stock units on 03/02/2026. The filing also lists two sales by Gina Mazzariello of 3,448 shares on 02/02/2026 and 3,419 shares on 02/23/2026.
Amylyx Pharmaceuticals Chief Legal Officer Gina Mazzariello reported an automatic sale of company stock tied to tax withholding. On February 23, 2026, she sold 3,419 shares of common stock in open-market transactions at a weighted average price of $14.1422 per share. The filing explains these shares were sold automatically to cover tax obligations from the vesting of restricted stock units, not at her discretion. After these transactions, she beneficially owned 141,274 shares of Amylyx common stock.
AMLX reports a proposed sale of Common stock tied to the vesting of Restricted Stock Units, totaling 10,250 shares with an anticipated action date of 02/23/2026. The filing also records that Gina Mazzariello sold 3,448 shares on 02/02/2026.
Amylyx Pharmaceuticals Inc. received an updated ownership filing showing that investment entities affiliated with TCG Crossover hold a significant passive stake in its common stock. TCG Crossover Fund II, L.P., together with its general partner TCG Crossover GP II, LLC and Chen Yu, report beneficial ownership of 6,243,812 shares.
This position represents 5.7% of Amylyx’s outstanding common stock, based on 109,819,659 shares outstanding as of October 27, 2025. The reporting parties state they share voting and dispositive power over these shares and certify the holdings are not for the purpose of changing or influencing control of the company.
Adage Capital Management, L.P. and related individuals report beneficial ownership of 2,777,055 shares of Amylyx Pharmaceuticals common stock, representing 2.53% of the outstanding shares. The shares are held with shared voting and dispositive power and reflect ownership of 5 percent or less of the class.
The filing is an amended Schedule 13G indicating a passive investment. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Amylyx Pharmaceuticals.
FMR LLC has filed an amended Schedule 13G reporting a significant ownership stake in Amylyx Pharmaceuticals Inc. common stock. FMR and related entities beneficially own 16,468,419 shares, representing 15.0% of the outstanding common stock as of the event date.
The filing lists FMR with sole voting power over 16,417,957 shares and sole dispositive power over 16,468,419 shares. Abigail P. Johnson is reported with sole dispositive power over the same 16,468,419 shares. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Amylyx.
Amylyx Pharmaceuticals, Inc. Chief Financial Officer James M. Frates reported an automatic sale of common stock tied to equity compensation taxes. On February 2, 2026, he sold 3,557 shares of Amylyx common stock at a weighted average price of $14.6463 per share to cover tax withholding from vesting restricted stock units. After this transaction, he directly held 173,547 shares, with additional shares held in several family trusts where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.